Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares traded -0.78% lower at $10.88 on Wall Street last session.
IOVA stock price is now -20.22% away from the 50-day moving average and 27.95% away from the 200-day moving average. The market capitalization of the company currently stands at $3.04B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $12, Goldman recently initiated with Buy rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA). On September 18, 2023, Barclays reiterated its ‘Overweight’ rating on the stock by increasing its target price from $40 to quote $18, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Rothbaum Wayne P., Director bought 5,000,000 shares of the company’s stock on Feb 20 ’24. The stock was bought for $45,750,000 at an average price of $9.15. Upon completion of the transaction, the Director now directly owns 28,067,333 shares in the company, valued at $305.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’24, Director MCPEAK MERRILL A bought 250,000 shares of the business’s stock. A total of $2,287,500 was incurred on buying the stock at an average price of $9.15. This leaves the insider owning 320,150 shares of the company worth $3.48 million. A total of 20.98% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $3.21 and a high of $18.33. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 4.63, and a quick ratio of 4.42.
According to the Biotechnology Company, earnings per share came in at -0.47, beating analysts’ expectations of -0.8 by 0.33. This compares to -$0.50 EPS in the same period last year. The net profit margin was -23615.70% and return on equity was -66.77% for IOVA. For the current quarter, analysts expect IOVA to generate $32.67M in revenue.
